Figure 5.
Demonstration of Antitumor Response by Neoantigen-Pulsed DCs Therapy
(A) Immunogenicity of neoantigen in vivo using prophylactic tumor model. Bone-marrow-derived dendritic cells (BM-DCs) were generated as previously reported. Each peptide-pulsed BM-DC (1×106/mouse) was intravenously injected twice to WT mice at day 14 and 7. Immunized mice were challenged with 1 × 105 MC38 tumor cells s.c. Tumor growth was monitored at indicated time points (mean ± SEM, n = 8/group).
(B) MutCry1-peptide-pulsed DCs (1 × 106/mouse) were administered to WT mice. Vaccinated mice were challenged with 1 × 105 MC38 tumor cells. In some experiments, mice were treated with anti-CD4 Ab or anti-CD8 Ab 2 days before tumor injection and repeatedly during tumor monitoring. Tumor growth was monitored at indicated time points (mean ± SEM, n = 7/group). Data are pooled from two independent experiments and analyzed by one-way ANOVA followed by Turkey's multiple comparison test. ∗∗p < 0.001, ∗∗∗p < 0.001.